Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 clinical trial evaluating monotherapy with BCD-264 and Darzalex in relapsed and refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma [Phase 2]
Phase II trial evaluating lenalidomide with subcutaneous bortezomib and dexamethasone for newly diagnosed multiple myeloma; results have bee…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Vaccine Therapy in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating a vaccine therapy in patients with stage II/III multiple myeloma; study completed.
-
CLINICAL_TRIALS trial_result · 2024-02-29Clinical Trial Update: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma [Phase 2, Phase 3]
Clinical trial update evaluating rivaroxaban versus aspirin for thromboprophylaxis in relapsed or progressive multiple myeloma (Phase 2/Phas…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 trial assessing carfilzomib in combination with bendamustine and dexamethasone for refractory or relapsed multiple myeloma has c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer [Phase 2]
Phase 2 trial evaluating romiplostim to treat low platelets after chemotherapy and autologous hematopoietic cell transplantation in people w…
-
CLINICAL_TRIALS trial_result · 2024-02-13Clinical Trial Update: Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM [Phase 2]
Phase 2 clinical study evaluating reduced-dose pomalidomide and cyclophosphamide with dexamethasone for relapsed/refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells as consolidation after autolog…
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement [Phase 2]
Phase 2 clinical trial investigating selinexor, pomalidomide, and dexamethasone for multiple myeloma with CNS involvement.
-
CLINICAL_TRIALS trial_result · 2024-01-25Clinical Trial Update: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update on KQ-2003 CAR-T cell therapy for relapsed or refractory multiple myeloma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone [Phase 2]
Phase 2 trial evaluating subcutaneous Velcade combined with oral melphalan and prednisone or cyclophosphamide and prednisone or prednisone a…
-
CLINICAL_TRIALS trial_result · 2024-01-19Clinical Trial Update: Selinexor, Cyclophosphamide and Prednisone in Myeloma [Phase 2]
Phase 2 clinical trial evaluating selinexor in combination with cyclophosphamide and prednisone for relapsed or refractory multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase 1 trial of AMG 420 in relapsed and/or refractory multiple myeloma was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma [Phase 4]
Phase 4 study evaluating safety, tolerability, and efficacy of Kyprolis (carfilzomib) in relapsed or refractory multiple myeloma has complet…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab [Phase 2]
This clinical trial update reports results from a Phase 2 study of retreatment with daratumumab in patients with multiple myeloma who had pr…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) [Phase 1, Phase 2]
Clinical trial update for Zevor-cel (CT053) in relapsed/refractory multiple myeloma (LUMMICAR STUDY 2) spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 [Phase 3]
A Phase 3 randomized trial in multiple myeloma compares lenalidomide, bortezomib, and dexamethasone (RVd) against high-dose chemotherapy wit…
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) [Phase 2]
Phase 2 clinical trial update evaluating Uproleselan (GMI-1271) for prophylaxis of GI toxicity during melphalan-conditioned autologous stem …
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma [Phase 2]
Phase 2 trial update of a second autologous stem cell transplant regimen using Elo-Pom-Dex for relapsed multiple myeloma; results were poste…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin [Phase 3]
Phase 3 trial update characterizing corneal epithelial changes in participants treated with belantamab mafodotin; study terminated with resu…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Maintenance Therapy With Subcutaneous Bortezomib [Phase 2]
Phase 2 trial evaluating maintenance therapy with subcutaneous bortezomib in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
A completed all-case surveillance trial evaluating NINLARO (ixazomib) capsules for relapsed/refractory multiple myeloma with posted results.
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM [Phase 2]
Phase 2 study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma has completed and posted result…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: ATG-010(Selinexor) in Combination With Chemotherapy in RRMM [Phase 2]
Phase 2 clinical trial update for ATG-010 (Selinexor) combined with chemotherapy in relapsed refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]
Clinical trial evaluating pomalidomide and dexamethasone with or without ixazomib for relapsed multiple myeloma across Phase 1 and Phase 2.